HPV


Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Wikipedia.

HPV

References in periodicals archive ?
Differences in prevalence of positive results for high-risk HPV or HPV-16/18, categorized by patient's age, sex, race/ ethnicity, and the anatomic location of cancer, were evaluated by using the [chi square] or Fisher exact test whenever possible.
2007;79:1169-75), and POBASCAM, a large Dutch study of more than 18,000 women (Lancet 2007;370:1764-72), both compared HPV testing combined with Pap cytology (cotesting) to cytology alone.
The quadrivalent HPV vaccine, Gardasil, elicits immune responses against HPV-6, HPV-11, HPV-16, and HPV-18 in men who have sex with men (MSM), HIV-positive men, and HIV-positive women.
In 3 of the patients with abnormal cytology and HPV 90 infection, in situ hybridization (ISH) for HR-HPV was performed on the available current biopsies according to the protocol provided by the manufacturer (INFORM HPV III Family 16 (B), Ventana Medical Systems Inc, Tucson, Arizona).
The investigators defined high-risk HPV clearance as a positive high-risk HPV result followed by two consecutive negative results.
In time, this unique patient dataset will provide a vital comparison group, against which the success of the HPV vaccination programme in Wales can be directly measured.
Daley noted that because the HPV vaccine was first approved for females in 2006 and for males in 2009, vaccine advocates lost years of opportunity to reach boys, their parents and young men with critical messaging around the importance of the vaccine for male health.
Cervical cancer screening is a success because squamous cell cervical cancer follows a predictable course from initial HPV infection to premalignant cellular changes to cancer, which takes an average of 9 - 15 years (Figs 1 and 2).
In girls and young women ages 9 to 26, GARDASIL helps protect against 2 types of HPV that cause about 75% of cervical cancer cases, and 2 more types that cause 90% of genital warts cases.
Moreover, the researchers found that the presence of HPV in one partner was the strongest predictor of finding the same HPV type in the other partner.
The fact that cervical cancer is caused by persistent infection by one or more of the high-risk oncogenic HPV types provides the exciting opportunity for prevention through vaccination.
Co-testing, specifically with an mRNA-based HPV assay, would be more clinically effective and cost less money overall to the health care system than screening with a DNA-based HPV test alone.